Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer

Frontiers Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies

IJMS, Free Full-Text

Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer - ScienceDirect

Cancers, Free Full-Text

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future - The Lancet

PDF] Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer